Overview

Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2020-09-11
Target enrollment:
Participant gender:
Summary
To compare the efficacy between the HLX01 group and the placebo group through the proportion of subjects meeting the ACR20 improvement criteria for remission
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Henlius Biotech
Treatments:
Antibodies, Monoclonal
Methotrexate
Rituximab